Medtronic plc (MDT)
| Market Cap | 107.36B -2.5% |
| Revenue (ttm) | 36.36B +8.4% |
| Net Income | 4.80B +3.0% |
| EPS | 3.73 +3.3% |
| Shares Out | 1.28B |
| PE Ratio | 22.49 |
| Forward PE | 14.10 |
| Dividend | $2.84 (3.39%) |
| Ex-Dividend Date | Jun 26, 2026 |
| Volume | 7,191,948 |
| Open | 82.83 |
| Previous Close | 82.39 |
| Day's Range | 82.56 - 84.19 |
| 52-Week Range | 73.31 - 106.33 |
| Beta | 0.58 |
| Analysts | Buy |
| Price Target | 97.73 (+16.53%) |
| Earnings Date | Aug 18, 2026 |
About MDT
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and rem... [Read more]
Financial Performance
In fiscal year 2026, Medtronic's revenue was $36.36 billion, an increase of 8.43% compared to the previous year's $33.54 billion. Earnings were $4.80 billion, an increase of 2.98%.
Financial StatementsAnalyst Summary
According to 30 analysts, the average rating for MDT stock is "Buy." The 12-month stock price target is $97.73, which is an increase of 16.53% from the latest price.
News
Leerink sees CPT proposal as ‘clear net positive’ signal for Medtronic
Leerink notes that the AMA CPT Editorial Panel released the Proposed Panel Agenda for their September 2026 CPT Editorial Panel Meeting and will review a proposal to establish Category I…
Medtronic price target lowered to $100 from $119 at TD Cowen
TD Cowen lowered the firm’s price target on Medtronic (MDT) to $100 from $119 and keeps a Buy rating on the shares. The firm expects CAS to be the primary…
Medtronic price target lowered to $105 from $106 at Evercore ISI
Evercore ISI lowered the firm’s price target on Medtronic (MDT) to $105 from $106 and keeps an Outperform rating on the shares. The firm’s Q2 preview for MedTech, Life Sciences…
This Undervalued Medical-Devices Stock Is Poised for a Rebound
Medtronic offers high growth potential in addition to discounted valuation.
Medtronic completes acquisition of Scientia Vascular, seamlessly integrating access and therapeutic portfolios for neurovascular care
Acquisition delivers simplicity and access, supporting physicians across the full procedural workflow GALWAY, Ireland, June 12, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healt...
Medtronic price target lowered to $95 from $110 at BofA
BofA lowered the firm’s price target on Medtronic (MDT) to $95 from $110 and keeps a Buy rating on the shares. Noting that the firm’s services team continues to highlight…
As Tech Stocks Slide, The Healthcare Sector Shines. Why Some Experts Say They Like This Defensive Play
Tech stocks are pulling back, and healthcare is surging.
Medtronic price target lowered to $83 from $84 at Goldman Sachs
Goldman Sachs analyst David Roman lowered the firm’s price target on Medtronic (MDT) to $83 from $84 and keeps a Neutral rating on the shares. The company’s Q4 results carried…
Medtronic price target lowered to $97 from $112 at Bernstein
Bernstein analyst Lee Hambright lowered the firm’s price target on Medtronic (MDT) to $97 from $112 and keeps an Outperform rating on the shares following a solid Q4. After weaker…
Medtronic price target lowered to $86 from $95 at Truist
Truist lowered the firm’s price target on Medtronic (MDT) to $86 from $95 and keeps a Hold rating on the shares. The company delivered a Q4 organic revenue beat but…
Medtronic price target lowered to $85 from $93 at Baird
Baird analyst David Rescott lowered the firm’s price target on Medtronic (MDT) to $85 from $93 and keeps a Neutral rating on the shares. The firm updated its model following…
Medtronic price target lowered to $85 from $90 at UBS
UBS analyst Priya Sachdeva lowered the firm’s price target on Medtronic (MDT) to $85 from $90 and keeps a Neutral rating on the shares. Medtronic’s solid Q4 results and seemingly…
Medtronic management to meet with Piper Sandler
Meeting to be held in Los Angeles on June 10-11 hosted by Piper Sandler.
Medtronic upgraded to Buy at BTIG on consistent organic growth
BTIG upgraded Medtronic (MDT) to Buy from Neutral with a $90 price target Medtronic has demonstrated consistent mid-single digit organic growth the past several quarters and the trajectory is improvin...
Medtronic upgraded to Buy from Neutral at BTIG
BTIG upgraded Medtronic (MDT) to Buy from Neutral.
Medtronic price target lowered to $80 from $95 at Stifel
Stifel analyst Rick Wise lowered the firm’s price target on Medtronic (MDT) to $80 from $95 and keeps a Hold rating on the shares. Medtronic’s Affera pulsed-field-ablation technology continues to…
Medtronic price target lowered to $101 from $120 at Needham
Needham analyst Mike Matson lowered the firm’s price target on Medtronic (MDT) to $101 from $120 and keeps a Buy rating on the shares. The company’s Q4 revenue and EPS…
Medtronic Earnings Call Transcript: Q4 2026
Q4 and FY26 delivered strong revenue and EPS growth, with robust performance across key segments and significant progress in innovation and portfolio focus. FY27 guidance anticipates continued top-line acceleration, margin leverage, and ongoing investment despite tariff and macro headwinds.
Medtronic Earnings release: Q4 2026
Medtronic released its Q4 2026 earnings on June 3, 2026, summarizing the period's financial results.
Medtronic Slides: Q4 2026
Medtronic has posted slides in relation to its Q4 2026 quarterly earnings report, which was published on June 3, 2026.
Medtronic Annual report: Q4 2026
Medtronic has published its Q4 2026 annual report on June 3, 2026.
Medtronic Stock Rises on Earnings. Wall Street Looks Past a Soft Outlook.
The medical device maker posts fiscal fourth-quarter earnings and revenue that narrowly beat analysts' estimates.
Medtronic Posts Higher Profit, Sales
Medtronic said its profit and sales rose during its fiscal fourth quarter, reflecting steps the company has taken to improve business performance and drive growth.
Medtronic submits 510(k) filings to expand Hugo™ robotic-assisted surgery system into general and gynecologic specialties in the United States
Company also announces 510(k) pending for LigaSure™ RAS Maryland instrument on the Hugo RAS system, and 510(k) clearance for ProGrip™ Advanced self-gripping polypropylene mesh for use in robotic-assis...